Cancer prevention is action taken to lower the chance of getting cancer. By preventing cancer, the number of new cases of cancer in a group or population is lowered. Hopefully, this will lower the number of deaths caused by cancer.
To prevent new cancers from starting, scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a cancer risk factor; anything that decreases your chance of developing cancer is called a cancer protective...
Revised text to state that between 1975 and 2010, childhood cancer mortality decreased by more than 50%.
Treatment of Newly Diagnosed Childhood Soft Tissue Sarcoma
Added text to state that a retrospective review of children who underwent surgery for desmoid tumors at the St. Jude Children's Research Hospital reported no correlation between surgical margins and risk of recurrence (cited Soto-Miranda et al. as reference 20).
Added Sulkowski et al. as reference 36.
Added text to state that in a series of nine patients, four patients who had a complete resection achieved continuous remission, three patients who had residual disease had a high recurrence rate and achieved continuous remission, and one patient who had metastatic disease responded to multiagent chemotherapy (cited Mehta et al. as reference 55 and level of evidence 3iiA).
Added text to state that a series of 51 pediatric patients aged 0 to 21 years with alveolar soft part sarcoma found an overall survival (OS) rate at 10 years of 78% and an event-free survival (EFS) rate of about 63%. Patients with localized disease had a 10-year OS of 87%, and the 14 patients with metastases at diagnosis had a 10-year OS of 44%. Only 3 of 18 patients with measurable disease had a response to conventional antisarcoma chemotherapy, but two of four patients treated with sunitinib had a partial response (cited Orbach et al. as reference 85 and level of evidence 3iiiA). Also added text to state that there have been sporadic reports of objective responses to interferon-alpha and bevacizumab; and that in a phase II trial of cediranib, 15 of 43 patients with metastatic alveolar soft part sarcoma had a partial response (cited Kummar et al. as reference 88 and level of evidence 3iiDiv).
Added text about the NCT00942877 and NCT01391962 trials as treatment options under clinical evaluation for alveolar soft part sarcoma.